Overview

Phase II Study of Single Agent Lenvatinib

Status:
Unknown status

Trial end date:
2021-03-28

Target enrollment:

Participant gender:

Summary

The Investigators hypothesize that single agent lenvatinib has biological activity in estrogen receptor positive breast cancer, and that the effects are more pronounced in patients with positive RET expression in the tumor.

Phase:

Phase 2

Details

Lead Sponsor:

National University Hospital, Singapore

Collaborators:

Eisai Co., Ltd.
Tan Tock Seng Hospital

Treatments:

Lenvatinib